Ruthenium-based complex nanocarriers for cancer therapy

Biomaterials. 2012 May;33(14):3770-82. doi: 10.1016/j.biomaterials.2012.01.057. Epub 2012 Feb 21.

Abstract

A new organometallic ruthenium complex, named AziRu, along with three amphiphilic nucleoside-based ruthenium complexes, ToThyRu, HoThyRu and DoHuRu, incorporating AziRu in their skeleton, have been synthesized, stabilized in POPC phospholipid formulations and studied for their antineoplastic activity. Self-aggregation behavior of these complexes was investigated, showing that the three synthesized AziRu derivatives able to form liposomes and, under specific conditions, elongated micelles. The formulations prepared in POPC proved to be stable for months and showed high in vitro antiproliferative activity. The here described results open new scenarios in the design of innovative transition metal-based supramolecular systems for anticancer drugs vectorization.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / chemistry
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Drug Carriers
  • Drug Stability
  • Humans
  • Liposomes
  • Materials Testing
  • Microscopy, Fluorescence
  • Nanoparticles / administration & dosage*
  • Nanoparticles / chemistry
  • Neoplasms / drug therapy*
  • Organometallic Compounds / administration & dosage*
  • Organometallic Compounds / chemistry
  • Rats
  • Ruthenium / administration & dosage*
  • Ruthenium / chemistry

Substances

  • Antineoplastic Agents
  • Drug Carriers
  • Liposomes
  • Organometallic Compounds
  • Ruthenium